Repare Therapeutics, Debiopharm dose first patient in Module 4 of MYTHIC trial

Repare Therapeutics and Debiopharm announced that the first patient has been dosed in Module 4 of the ongoing Phase 1/1b MYTHIC clinical trial investigating lunresertib in combination with Debio 0123. In this trial, Debiopharm and Repare seek to assess the safety, pharmacokinetics, pharmacodynamics and preliminary clinical activity of this PKMYT1 and WEE1 inhibitor combination.